Follicular lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma. Despite treatment advances that have improved outcomes for patients with relapsed or refractory (R/R) FL, many patients still die from progressive disease or treatment-related toxicities. In the phase Ib/II GO29365 study (clinicaltrials.gov 02257567), the safety and efficacy of polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) versus bendamustine and rituximab (BR) alone, and polatuzumab vedotin plus bendamustine and obinutuzumab (Pola-BG) as a single-arm cohort were evaluated in patients with R/R FL. Following the phase Ib safety run-in, patients were randomized 1:1 to receive Pola-BR or BR alone in the phase II stage; a separate non-randomized Pola-BG cohort was examined in the phase Ib/II expansion stage. Primary endpoints included safety and tolerability (phase Ib) and positron emission tomography complete response (PET-CR) rate by independent review committee (phase II). Overall, 112 patients were enrolled (phase Ib safety run-in: Pola-BR, N=6; phase II randomized cohort: Pola-BR, N=39; BR, N=41; phase Ib/II expansion cohort: Pola-BG, N=26). PET-CR rates were 66.7% (phase Ib safety run-in, Pola-BR); 69.2% (phase II randomized, Pola-BR); 63.4% (phase II randomized, BR); and 65.4% (phase Ib/II expansion Pola-BG). There was a higher occurrence of cytopenias with Pola-BR and Pola-BG than with BR; serious adverse events were more frequent with Pola-BR (61.4%) and Pola-BG (46.2%) than with BR (29.3%). Overall, this analysis does not demonstrate a benefit of adding Pola to BR or BG regimens for patients with R/R FL.

BC Cancer Centre for Lymphoid Cancer and The University of British Columbia Vancouver BC

Center for Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham

Charles University General Hospital Prague Czech Republic

City of Hope Medical Centre Duarte CA

Clinical Haematology Monash Health and Monash University Clayton

Genentech Inc South San Francisco CA

Jewish General Hospital Montreal QC

Memorial Sloan Kettering Cancer Center New York NY

Prince of Wales Hospital and University of NSW Sydney

Semmelweiss University Budapest Hungary

University of Alabama at Birmingham Birmingham

Winship Cancer Institute of Emory University Atlanta GA

Zobrazit více v PubMed

Monga N, Nastoupil L, Garside J, et al. . Burden of illness of follicular lymphoma and marginal zone lymphoma. Ann Hematol. 2019;98(1):175-183. PubMed

Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. Blood. 2019;133(14):1540-1547. PubMed

Salles G. How do I sequence therapy for follicular lymphoma? Hematology Am Soc Hematol Educ Program. 2020;2020(1):287-294. PubMed PMC

Sarkozy C, Maurer MJ, Link BK, et al. . Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37(2):144. PubMed PMC

Dornan D, Bennett F, Chen Y, et al. . Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721-2729. PubMed

Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs. 2011;20(1):75-85. PubMed

Doronina SO, Toki BE, Torgov MY, et al. . Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778-784. PubMed

Assi R, Masri N, Abou Dalle I, et al. . Polatuzumab vedotin: current role future applications in the treatment of patients with diffuse large B-cell lymphoma. Clin Hematol Int. 2021;3(1):21. PubMed PMC

Sehn LH, Herrera AF, Flowers CR, et al. . Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155. PubMed PMC

European Medicines Agency. POLIVY® Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/polivy-epar-product-information_en.pdf. Accessed December 1, 2022.

U.S. Food and Drug Administration. POLIVY® Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/ label/2023/761121s008lbl.pdf. Accessed December 1, 2022.

Hiddemann W, Barbui AM, Canales MA, et al. . Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36(23):2395-2404. PubMed

Townsend W, Hiddemann W, Buske C, et al. . Obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: final analysis of the GALLIUM study. Hemasphere. 2022;6(S3):107-108.

Sehn LH, Herrera AF, Flowers CR, et al. . Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155-165. PubMed PMC

Sehn LH, Hertzberg M, Opat S, et al. . Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533-543. PubMed PMC

World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79(4):373-374. PubMed PMC

Brice P, Bastion Y, Lepage E, et al. . Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15(3):1110-1117. PubMed

Smith TJ, Bohlke K, Lyman GH, et al. . Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(28):3199-3212. PubMed

Cheson BD, Fisher RI, Barrington SF, et al. . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068. PubMed PMC

Cheson BD, Chua N, Mayer J, et al. . Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018;36(22):2259-2266. PubMed

Leonard JP, Trneny M, Izutsu K, et al. . AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188-1199. PubMed PMC

Tilly H, Morschhauser F, Bartlett NL, et al. . Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019;20(7):998-1010. PubMed

Hagemeister F, Manoukian G. Bendamustine in the treatment of non-Hodgkin’s lymphomas. Onco Targets Ther. 2009;2:269-279. PubMed PMC

Rummel MJ, Niederle N, Maschmeyer G, et al. . Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-1210. PubMed

Erblich T, Montoto S. Treating relapsed follicular lymphoma. Expert Rev Hematol. 2018;11(5):403-410. PubMed

Ghielmini M, Schmitz S, Cogliatti S, et al. . Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103(12):4416-4423. PubMed

Liewer S. Toxicity of bendamustine therapy. The Oncology Pharmacist. 2021. https://www.theoncologypharmacist.com/cat egories?view=article&secid=15091:faculty-perspectives-may-2013-vol-4-no-3-top&artid=15761:toxicity-of-bendamustine-therapy&catid=4022. Accessed September 14, 2023.